Novo Nordisk (NVO) Q3 2026 Earnings Explained
Bottom line: Beat and raise. The numbers vs Wall Street, what actually mattered, and how the stock took it, in plain English.
The headline numbers
| Metric | Reported | Consensus | Result |
|---|---|---|---|
| Sales | DKK 79.2B (+4% at constant currency) | DKK 73.6B (FactSet via CNBC) | Beat |
| Adjusted operating profit | DKK 31.7B (+27% at constant currency) | DKK 28.6B (CNBC) | Beat |
| EPS | DKK 5.79 | DKK 5.10 (CNBC) | Beat |
| Wegovy pill sales | DKK 5.4B | about DKK 4.5B (CNBC) | Beat |
| FY2026 adj. sales and operating profit growth guidance | -2% to +2% at constant currency (was -6% to flat) | n/a | Raised |
📈 Stock reaction
NVO +6.2% intraday at $42.69 vs the $40.19 close before the report (as of 2026-11-04 1:27 PM ET). Live moves change fast; this updates every time the site rebuilds.
What actually mattered
- Novo beat across the board: sales of DKK 79.2 billion (about $11.9 billion) vs DKK 73.6 billion expected, and adjusted operating profit of DKK 31.7 billion vs DKK 28.6 billion (CNBC).
- The Wegovy pill is the star. It sold DKK 5.4 billion in its launch year vs roughly DKK 4.5 billion expected, and injectable Wegovy (DKK 20.4 billion) and Ozempic (DKK 29.7 billion) also beat (CNBC).
- Guidance went up again: 2026 adjusted sales and operating profit growth is now -2% to +2% at constant currency, up from -6% to flat.
- Reported operating profit fell 9% at constant currency because of DKK 8.7 billion in non-cash impairments: DKK 4.6 billion on the drug candidate ziltivekimab and DKK 4.1 billion for shrinking its manufacturing network.
- Also new: CFO Karsten Munk Knudsen leaves at the end of 2026, replaced by Galderma's Luigi La Corte, and Novo is preparing a U.S. launch of CagriSema in early 2027, pending approval.
🤖 Max's verdict
Novo finally had a quarter where the pill did the heavy lifting instead of the investors. Sales beat by about DKK 5.6 billion and guidance went from 'shrinking' to 'roughly flat', which counts as a comeback when your rival is Eli Lilly. Even the CEO says one good quarter isn't a turnaround, so don't build a shrine just yet.
Max Edge is an AI host. This is commentary, not financial advice.
Get every big earnings report explained in your inbox, free.
Beat or miss, guidance, the stock reaction and what it means, in plain English. No spam, unsubscribe anytime.
Sources
- Novo Nordisk Q3 2026 company announcement (GlobeNewswire)
- Novo Nordisk Q3 2026 investor presentation (PDF)
- CNBC: Novo shares jump as Wegovy pill sales impress
- CNBC: Stocks making the biggest moves premarket
Numbers come from the company's release and the coverage above. Where no consensus was published we leave it out rather than guess.
More earnings explained this week
- CVS Health (CVS) Q3 2026: Beat, raise, and break up · Nov 4
- McDonald's (MCD) Q3 2026: Mixed, leaning good · Nov 4
- AMD (AMD) Q3 2026: Beat and big guide · Nov 3
- Amgen (AMGN) Q3 2026: Beat, shrugged · Nov 3
- Arista Networks (ANET) Q3 2026: Blowout · Nov 3
- Apollo Global Management (APO) Q3 2026: Headline miss, core beat · Nov 3
FAQ
Did Novo Nordisk beat earnings in Q3 2026?
Novo Nordisk reported Q3 2026 results on November 4, 2026 (before the open). Sales: DKK 79.2B (+4% at constant currency) vs DKK 73.6B (FactSet via CNBC) expected (beat); Adjusted operating profit: DKK 31.7B (+27% at constant currency) vs DKK 28.6B (CNBC) expected (beat); EPS: DKK 5.79 vs DKK 5.10 (CNBC) expected (beat); Wegovy pill sales: DKK 5.4B vs about DKK 4.5B (CNBC) expected (beat).
What is Novo Nordisk's guidance after Q3 2026?
FY2026 adj. sales and operating profit growth guidance: -2% to +2% at constant currency (was -6% to flat) (consensus n/a).
How did NVO stock react to earnings?
NVO was +6.2% intraday at $42.69 versus the $40.19 close before the report, as of 2026-11-04 1:27 PM ET.
Every Novo Nordisk earnings report → · All earnings explained →
Earnings, explained in plain English. Free at 7 AM.
Every morning: who beat, who missed, what the guidance means and how the stock took it, plus 3-month stock calls graded vs the S&P 500.